Astellas Pharma Inc.
ALPMF | OTC
$16.15
-$1.35 (-7.71%)
At close: Nov 5, 2026, 3:14 PM ET
$17.50
+$1.35 (+8.36%)
After-hours:
Nov 4, 2026, 4:00 PM ET
-7.71%
(1D)No price chart data available for 1D timeframe.
Rating
73.8
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #37/1024 (Top 4%)
Key Statistics
Market Data
Market Cap $28.96B
1D Range
16.15 17.50
52W Range
11.00 17.60
Valuation (TTM)
PE 13.29
PB 2.62
EV/EBITDA 8.04
Valuation (NTM)
Forward PE 13.19
Forward PEG 0.38
Price Target $0.00
Cash Flow
FCF Yield 10.9%
SBC Adj. FCF Yield 10.9%
SBC Impact N/A
Margins
Gross Margin 74.7%
Operating Margin 21.8%
FCF Margin 23.8%
Growth (CAGR)
Revenue 3Y | 5Y 14.6% |
12.4%
Dil EPS 3Y | 5Y 51.2% |
30.2%
FCF 3Y | 5Y 27.9% |
13.0%
Returns
ROA 9.9%
ROE 20.4%
ROIC 14.0%
Financial Health
Net Debt
¥345.17B ($2.12B)
Current Ratio 1.20
Interest Coverage 43.91
Dividends
Div Yield 2.86%
Payout Ratio 0.3%
FCF Payout Ratio 25.9%
Loading financial charts...
Profile
Astellas Pharma Inc. operates as a global pharmaceutical enterprise, encompassing the development, manufacturing, distribution, and commercialization of medicinal products across international markets...
Sector Healthcare
Industry Drug Manufacturers - General
Employees 14,099
IPO Date Apr 26, 2010
Website www.astellas.com
Fiscal Year April - March
Latest News
3 months ago · seekingalpha.com
Impax International Sustainable Economy Fund Q2 2026 Contributors And DetractorsThe portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata Manufacturing, SoftBank Group and Astellas Pharma.
Earnings
Latest Earnings
Nov 4, 2026
EPS
$0.35
Miss -14.38%
YoY:
+18.33% REV
$4B
Beat +6.32%
YoY:
+12.91%Next Earnings
Feb 8, 2027
EPS Est
Pro
Rev Est
Pro
Add to Watchlist
Select watchlists to add or remove ALPMF